International Journal of Clinical Practice

Metabolic approach to heart failure - evidence that trimetazidine improves symptoms, left ventricular function and possibly prognosis
pp. 891-892(2)
Author: Jackson, Graham

CATIE for clinicians
pp. 892-893(2)
Author: Kerwin, R.

PDE-5 inhibitors: spoilt for choice
pp. 893-894(2)
Author: Kirby, M. G.

Measuring the impact of childhood atopic dermatitis
pp. 895-895(1)
Author: Graham-Brown, R.

Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study
pp. 896-905(10)
Authors: COOPER, A.; DRAKE, J.; BRANKIN, E.

Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study
pp. 906-910(5)
Authors: KUO, C-S; PEI, D.; YAO, C-Y; HSIEH, M-C; KUO, S-W

A double-blind randomised trial to evaluate the effect of anastrozole for the treatment of non-toxic multinodular goitre
pp. 911-913(3)
Authors: KNIGHT, J. S.; SATCHIDANAND, R. Y.; YIANGOU, C.; JACKSON, A.; CUMMINGS, M. H.

Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia
pp. 914-921(8)
Authors: PATEL, J. V.; HUGHES, E. A.

A cost-effectiveness analysis of n-3 PUFA (Omacor^®) treatment in post-MI patients
pp. 922-932(11)
Authors: QUILICI, S.; MARTIN, M.; MCGUIRE, A.; ZOELLNER, Y.

Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?
pp. 933-940(8)
Authors: CITROME, L.; STROUP, T. SCOTT

Management of advanced chronic kidney disease in primary care - current data from Germany
pp. 941-948(8)
Authors: HERGET-ROSENTHAL, S.; QUELLMANN, T.; LINDEN, C.; REINHARDT, W.; PHILIPP, T.; KRIBBEN, A.

Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care
pp. 949-958(10)
Authors: ODEYEMI, I. A. O.; DAKIN, H. A.; O'DONNELL, R. A.; WARNER, J.; JACOBS, A.; DASGUPTA, P.

Solifenacin significantly improves all symptoms of overactive bladder syndrome
pp. 959-966(8)
Authors: CHAPPLE, C. R.; CARDOZO, L.; STEERS, W. D.; GOVIER, F. E.

Comparison of phosphodiesterase type 5 (PDE5) inhibitors
pp. 967-975(9)
Author: WRIGHT, P. J.

Management of advanced HIV disease in patients with tuberculosis or hepatitis co-infection
pp. 976-983(8)
Authors: NELSON, M.; LIPMAN, M.

Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema
pp. 984-992(9)
Author: LEWIS-JONES, S.

Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors
pp. 993-1002(10)
Authors: MALININ, A. I.; ONG, S.; MAKAROV, L. M.; PETUKHOVA, E. Y.; SEREBRUANY, V. L.

Baclofen: a new drug for the treatment of alcohol dependence
pp. 1003-1008(6)
Authors: ADDOLORATO, G.; LEGGIO, L.; AGABIO, R.; COLOMBO, G.; GASBARRINI, G.

Response to: Ethics, data and the pharmaceutical physician
pp. 1009-1009(1)
Author: Dayan, A. D.

A reply: Ethics and Pharmaceutical Medicine
pp. 1009-1009(1)
Author: Paterson, K. R.

Response to: Angiotensin receptor blockers in hypertension: the emerging role in diabetes mellitus
pp. 1010-1012(3)
Authors: Varughese, G. I.; Scarpello, J. H. B.

Risk factors for vitamin D inadequacy among women with osteoporosis: an international epidemiological study
pp. 1013-1019(7)
Authors: RIZZOLI, R.; EISMAN, J. A.; NORQUIST, J.; LJUNGGREN, Ö.; KRISHNARAJAH, G.; LIM, S-K; CHANDLER, J.